Recro Pharma, Inc. (Nasdaq: REPH) announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE